1-855-378-42281-855-378-4228
One of the outpatient rehab alternatives for people in Mount Vernon battling with opioid dependence and addiction is called opioid maintenance therapy. Some facilities and doctors are certified to administer certain medications to opioid addicted people, many that are opioid-based themselves and are habit forming. With low amounts the client does not experience being high but also does not have intense cravings and isn't experiencing opioid withdrawal. Methadone is the first medication administered for this purpose, but there are a few more options currently to choose from.
Methadone is an opiate and can be taken at an out-patient medical center licensed to administer the med, which is taken on a daily basis in liquid or pill form. The cost of the med is approximately under $200 per month. Buprenorphine is also an opiate based drug, and is in pill form often taken every other day. But different from Methadone which is only be administered in highly well-regulated medical centers, Buprenorphine can be and is prescribed and administered in doctor's offices. The cost monthly of buprenorphine is approximately $300.00 a month for the generic version of the med. There is also a type of buprenorphine that contains naloxone, which is a drug which reverses the effects of opioids. An individual consuming this version of the drug, also known as Suboxone, would find it harder to feel high from opioids if they relapsed while taking the drug. It too is taken daily, and is priced about $450 a month. Naltrexone is another med taken in opioid maintenance therapy, but unlike the other medications mentioned it's an opiate blocker and isn't an opioid. There is an option to take this medication as a monthly shot, which is called Vivitrol. As an opioid blocker, it prevents a person from experience high feelings from opioids, and therefore lowers the risk associated with relapse. This daily shot costs anywhere from $1000 to $1200 monthly.
For All Drug and Alcohol Rehab Facilities In Mount Vernon, Click Here.
